Abstract |
We previously reported that brain-derived neurotrophic factor ( BDNF)/neurotrophic receptor tyrosine kinase 2 (NTRK2/TRKB) signaling contributes to induction of malignant phenotype of gallbladder cancer (GBC). Recently, pan-TRK inhibitors have been evaluated and their dramatic clinical activity is being shown for a variety of cancer types harboring an NTRK rearrangement in phase I trials. ONO-7579 is an oral pan-TRK inhibitor currently under investigation in phase I/II clinical trial for TRK-rearranged solid tumors. In this study, we evaluated the anticancer effect of ONO-7579 using GBC cells with or without KRAS mutant, NOZ, TYGBK-1. Our study showed that ONO-7579 had a suppressive effect on GBC proliferation in TYGBK-1, and on invasive potential and vascular endothelial growth factor expression in TYGBK-1 and NOZ. Our data indicated that ONO-7579 could be a promising treatment option for patients with GBC.
|
Authors | Makoto Kawamoto, Keigo Ozono, Yasuhiro Oyama, Akio Yamasaki, Yoshinao Oda, Hideya Onishi |
Journal | Anticancer research
(Anticancer Res)
Vol. 38
Issue 4
Pg. 1979-1986
(04 2018)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 29599313
(Publication Type: Journal Article)
|
Copyright | Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Brain-Derived Neurotrophic Factor
- Membrane Glycoproteins
- ONO-7579
- Organic Chemicals
- Protein Kinase Inhibitors
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- BDNF protein, human
- Receptor, trkB
- tropomyosin-related kinase-B, human
|
Topics |
- Brain-Derived Neurotrophic Factor
(antagonists & inhibitors)
- Cell Line, Tumor
- Cell Movement
(drug effects)
- Cell Proliferation
(drug effects)
- Epithelial-Mesenchymal Transition
(drug effects)
- Gallbladder Neoplasms
(drug therapy, enzymology, metabolism, pathology)
- Humans
- Membrane Glycoproteins
(antagonists & inhibitors, biosynthesis)
- Neoplasm Invasiveness
- Organic Chemicals
(chemistry, pharmacology)
- Protein Kinase Inhibitors
(pharmacology)
- Receptor, trkB
(antagonists & inhibitors, biosynthesis)
- Vascular Endothelial Growth Factor A
(biosynthesis)
|